UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | September 25, 2013 |
Endocyte,
Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 001-35050 | 35-1969-140 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana | 47906 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrant’s telephone number, including area code: | 765-463-7175 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Janssen Products, LP informed healthcare providers on September 25, 2013 of an anticipated interruption of supply of DOXIL® (doxorubicin HCI liposome injection). Endocyte’s Phase 3 PROCEED trial evaluating vintafolide and etarfolatide in women with platinum resistant ovarian cancer includes DOXIL® as the control drug. As previously disclosed, Endocyte has purchased a substantial supply of DOXIL® to support the PROCEED trial. This supply is expected to be sufficient to support patients currently on trial and new enrollment for the next 9-12 months, which would be beyond the interim analysis of the trial. Enrollment in the trial will continue uninterrupted in the meantime.
Endocyte will continue to collaborate with Janssen to ensure ongoing supply of DOXIL® in order to complete the PROCEED trial.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Endocyte, Inc. | ||||
September 26, 2013 | By: | /s/ Michael A. Sherman | ||
Name: Michael A. Sherman | ||||
Title: Chief Financial Officer |